Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Vascular Pharmacology
  4. Volume 23, Issue 1
  5. Article
Volume 23, Issue 1
  • ISSN: 1570-1611
  • E-ISSN: 1875-6212

Abstract

Aims

To assess the efficacy and safety of sarpogrelate (300 mg) for symptom improvement in patients having peripheral arterial disease (PAD) and/or being at risk of PAD in clinical practice using the Peripheral Artery Questionnaire (PAQ).

Background

Symptomatic changes with antiplatelets in patients with PAD are limited.

Objective

To determine the effect and safety of sarpogrelate on the PAQ at 24 weeks from baseline.

Methods

A total of 1003 patients having PAD and/or being at risk of PAD from 17 tertiary hospitals in South Korea who were treated with sarpogrelate, were enrolled in this study. PAQs were collected at baseline and at 12 and 24 weeks, together with physical examination and vital signs measurements. Lifestyle pattern was also investigated.

Results

The average PAQ Summary Score in the efficacy evaluation analysis group significantly improved from 62.9 ± 23.7 at baseline to 68.9 ± 21.7 at 24 weeks (<0.0001). Physical limitation items significantly improved from 69.5 ± 30.0 at baseline to 72.9 ± 28.3 after 24 weeks (=0.0011). Symptom stability also significantly improved from 52.1 ± 21.6 at baseline to 63.6 ± 22.9 after 24 weeks (<0.0001). Symptoms, treatment satisfaction, quality of life, and social limitation domains all improved after treatment. A total of 201 patients reported adverse events (20.0%), not directly associated with treatment.

Conclusion

Treatment with 300 mg (orally) of sarpogrelate demonstrated statistically significant improvements in all domains and for the summary score of the PAQ at 24 weeks, it gave good results in terms of safety. Sarpogrelate may be helpful in reducing symptoms related to PAD.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cvp/10.2174/0115701611285172241015074050
2024-10-22
2025-04-12

  • From This Site

    /content/journals/cvp/10.2174/0115701611285172241015074050
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. PatelM.R. ConteM.S. CutlipD.E. DibN. GeraghtyP. GrayW. HiattW.R. HoM. IkedaK. IkenoF. JaffM.R. JonesW.S. KawaharaM. LooksteinR.A. MehranR. MisraS. NorgrenL. OlinJ.W. PovsicT.J. RosenfieldK. RundbackJ. ShamounF. TchengJ. TsaiT.T. SuzukiY. VranckxP. WiechmannB.N. WhiteC.J. YokoiH. KrucoffM.W. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC).J. Am. Coll. Cardiol.201565993194110.1016/j.jacc.2014.12.03625744011
     [Google Scholar]
  2. SatohK. YatomiY. OzakiY. A new method for assessment of an anti‐5HT2A agent, sarpogrelate hydrochloride, on platelet aggregation.J. Thromb. Haemost.20064247948110.1111/j.1538‑7836.2006.01757.x16420586
     [Google Scholar]
  3. TenderaM. AboyansV. BartelinkM.L. BaumgartnerI. ClémentD. ColletJ.P. CremonesiA. De CarloM. ErbelR. FowkesF.G.R. HerasM. KownatorS. MinarE. OstergrenJ. PoldermansD. RiambauV. RoffiM. RötherJ. SievertH. van SambeekM. ZellerT. BaxJ. AuricchioA. BaumgartnerH. CeconiC. DeanV. DeatonC. FagardR. Funck-BrentanoC. HasdaiD. HoesA. KnuutiJ. KolhP. McDonaghT. MoulinC. PoldermansD. PopescuB. ReinerZ. SechtemU. SirnesP.A. TorbickiA. VahanianA. WindeckerS. KolhP. TorbickiA. AgewallS. BlincA. BulvasM. CosentinoF. De BackerT. GottsaterA. GulbaD. GuzikT.J. JonssonB. KesmarkyG. KitsiouA. KuczmikW. LarsenM.L. MadaricJ. MasJ-L. McMurrayJ.J.V. MicariA. MosseriM. MullerC. NaylorR. NorrvingB. OtoO. PasierskiT. PlouinP-F. RibichiniF. RiccoJ-B. RuilopeL. SchmidJ-P. SchwehrU. SolB.G.M. SpryngerM. TiefenbacherC. TsioufisC. Van DammeH. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * the task force on the diagnosis and treatment of peripheral artery diseases of the European society of cardiology (ESC).Eur. Heart J.201132222851290610.1093/eurheartj/ehr21121873417
     [Google Scholar]
  4. RookeT.W. HirschA.T. MisraS. SidawyA.N. BeckmanJ.A. FindeissL.K. GolzarianJ. GornikH.L. HalperinJ.L. JaffM.R. MonetaG.L. OlinJ.W. StanleyJ.C. WhiteC.J. WhiteJ.V. ZierlerR.E. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline).J. Am. Coll. Cardiol.201158192020204510.1016/j.jacc.2011.08.02321963765
     [Google Scholar]
  5. FowkesF.G.R. RudanD. RudanI. AboyansV. DenenbergJ.O. McDermottM.M. NormanP.E. SampsonU.K.A. WilliamsL.J. MensahG.A. CriquiM.H. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.Lancet201338299011329134010.1016/S0140‑6736(13)61249‑023915883
     [Google Scholar]
  6. KulloI.J. RookeT.W. Peripheral artery disease.N. Engl. J. Med.2016374986187110.1056/NEJMcp150763126962905
     [Google Scholar]
  7. DoggrellS.A. Sarpogrelate: cardiovascular and renal clinical potential.Expert Opin. Investig. Drugs200413786587410.1517/13543784.13.7.86515212624
     [Google Scholar]
  8. KhawajaF.J. KulloI.J. Novel markers of peripheral arterial disease.Vasc. Med.200914438139210.1177/1358863X0910686919808725
     [Google Scholar]
  9. MahoneyE.M. WangK. CohenD.J. HirschA.T. AlbertsM.J. EagleK. MosseF. JacksonJ.D. StegP.G. BhattD.L. One-year costs in patients with a history of or at risk for atherothrombosis in the United States.Circ. Cardiovasc. Qual. Outcomes200811384510.1161/CIRCOUTCOMES.108.77524720031786
     [Google Scholar]
  10. KulloI.J. LeeperN.J. The genetic basis of peripheral arterial disease: current knowledge, challenges, and future directions.Circ. Res.201511691551156010.1161/CIRCRESAHA.116.30351825908728
     [Google Scholar]
  11. AgnelliG. BelchJ.J.F. BaumgartnerI. GiovasP. HoffmannU. Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review.Atherosclerosis20202939410010.1016/j.atherosclerosis.2019.09.01231606132
     [Google Scholar]
  12. BhattD.L. StegP.G. OhmanE.M. HirschA.T. IkedaY. MasJ.L. GotoS. LiauC.S. RichardA.J. RötherJ. WilsonP.W. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.JAMA2006295218018910.1001/jama.295.2.18016403930
     [Google Scholar]
  13. VikenesK. FarstadM. NordrehaugJ.E. Serotonin is associated with coronary artery disease and cardiac events.Circulation1999100548348910.1161/01.CIR.100.5.48310430761
     [Google Scholar]
  14. PeachG. GriffinM. JonesK.G. ThompsonM.M. HinchliffeR.J. Diagnosis and management of peripheral arterial disease.BMJ2012345aug14 1e520810.1136/bmj.e520822893640
     [Google Scholar]
  15. KhaleghiM. IssehI.N. BaileyK.R. KulloI.J. Family history as a risk factor for peripheral arterial disease.Am. J. Cardiol.2014114692893210.1016/j.amjcard.2014.06.02925107577
     [Google Scholar]
  16. SigvantB. LundinF. WahlbergE. The risk of disease progression in peripheral arterial disease is higher than expected: A meta-analysis of mortality and disease progression in peripheral arterial disease.Eur. J. Vasc. Endovasc. Surg.201651339540310.1016/j.ejvs.2015.10.02226777541
     [Google Scholar]
  17. BauersachsR. BrodmannM. ClarkC. DebusS. De CarloM. Gomez-CerezoJ.F. MadaricJ. MazzolaiL. RiccoJ.B. SillesenH. AboyansV. International public awareness of peripheral artery disease.Vasa202150429430010.1024/0301‑1526/a00094533645232
     [Google Scholar]
  18. SartipyF. Garcia Pereira FilhoA.J. LundinF. WahlbergE. SigvantB. Presence of asymptomatic peripheral arterial disease in combination with common risk factors elevates the cardiovascular risk substantially.International Journal of Cardiology Cardiovascular Risk and Prevention20221320013010.1016/j.ijcrp.2022.20013035493293
     [Google Scholar]
  19. FiorettiV. GerardiD. GiuglianoG. Di FazioA. StabileE. Focus on prevention: Peripheral arterial disease and the central role of the cardiologist.J. Clin. Med.20231213433810.3390/jcm1213433837445373
     [Google Scholar]
  20. SainiH.K. TakedaN. GoyalR.K. KumamotoH. ArnejaA.S. DhallaN.S. Therapeutic potentials of sarpogrelate in cardiovascular disease.Cardiovasc. Drug Rev.2004221275410.1111/j.1527‑3466.2004.tb00130.x14978517
     [Google Scholar]
  21. LeeD.H. ChunE.J. HurJ.H. MinS.H. LeeJ.E. OhT.J. KimK.M. JangH.C. HanS.J. KangD.K. KimH.J. LimS. Effect of sarpogrelate, a selective 5-HT 2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes.Atherosclerosis2017257475410.1016/j.atherosclerosis.2016.12.01128068560
     [Google Scholar]
  22. TakahashiT. YanoM. MinamiJ. HaraguchiT. KogaN. HigashiK. KoboriS. Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy.Diabetes Res. Clin. Pract.200258212312910.1016/S0168‑8227(02)00105‑512213354
     [Google Scholar]
  23. LuJ.T. CreagerM.A. The relationship of cigarette smoking to peripheral arterial disease.Rev. Cardiovasc. Med.20045418919315580157
     [Google Scholar]
  24. HanA. LeeT. LeeJ. SongS.W. LeeS.S. JungI.M. KangJ.M. GwonJ.G. YunW.S. ChoY.P. KoH. ParkY.J. MinS.K. A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention.Sci. Rep.2023131250210.1038/s41598‑023‑29006‑z36781928
     [Google Scholar]
  25. YooH. ParkI. KimD.J. LeeS. Effects of sarpogrelate on microvascular complications with type 2 diabetes.Int. J. Clin. Pharm.201941256357310.1007/s11096‑019‑00794‑730864083
     [Google Scholar]
  26. HirschA.T. CriquiM.H. Treat-JacobsonD. RegensteinerJ.G. CreagerM.A. OlinJ.W. KrookS.H. HunninghakeD.B. ComerotaA.J. WalshM.E. McDermottM.M. HiattW.R. Peripheral arterial disease detection, awareness, and treatment in primary care.JAMA2001286111317132410.1001/jama.286.11.131711560536
     [Google Scholar]
  27. VioliF. BasiliS. BergerJ.S. HiattW.R. Antiplatelet therapy in peripheral artery disease.Handb. Exp. Pharmacol.201221021054756310.1007/978‑3‑642‑29423‑5_2222918746
     [Google Scholar]
  28. SpertusJ. JonesP. PolerS. Rocha-SinghK. The peripheral artery questionnaire: a new disease-specific health status measure for patients with peripheral arterial disease.Am. Heart J.2004147230130810.1016/j.ahj.2003.08.00114760329
     [Google Scholar]
  29. LeeJ.H. ChoK.I. SpertusJ. KimS.M. Cross-cultural adaptation and validation of the Peripheral Artery Questionnaire: Korean version for patients with peripheral vascular diseases.Vasc. Med.201217421522210.1177/1358863X1244510422653880
     [Google Scholar]
  30. JonesW.S. BaumgartnerI. HiattW.R. HeizerG. ConteM.S. WhiteC.J. BergerJ.S. HeldP. KatonaB.G. MahaffeyK.W. NorgrenL. BlomsterJ. MillegårdM. ReistC. PatelM.R. FowkesF.G.R. Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease.Circulation2017135324125010.1161/CIRCULATIONAHA.116.02588027840336
     [Google Scholar]
  31. Peri-OkonnyP.A. WangJ. GoschK.L. PatelM.R. ShishehborM.H. SafleyD.L. AbbottJ.D. AronowH.D. Mena-HurtadoC. JelaniQ.U.A. TangY. BunteM. LabroscianoC. BeltrameJ.F. SpertusJ.A. SmolderenK.G. Establishing thresholds for minimal clinically important differences for the peripheral artery disease questionnaire.Circ. Cardiovasc. Qual. Outcomes2021145e00723210.1161/CIRCOUTCOMES.120.00723233947205
     [Google Scholar]
  32. SmolderenK.G. HoeksS.E. AquariusA.E. Scholte op ReimerW.J. SpertusJ.A. van UrkH. DenolletJ. PoldermansD. Further validation of the peripheral artery questionnaire: results from a peripheral vascular surgery survey in the Netherlands.Eur. J. Vasc. Endovasc. Surg.200836558259110.1016/j.ejvs.2008.07.01518804390
     [Google Scholar]
  33. TranA.T. SpertusJ.A. Mena-HurtadoC.I. JonesP.G. AronowH.D. SafleyD.M. MalikA.O. Peri-OkonnyP.A. ShishehborM.H. LabroscianoC. SmolderenK.G. Association of Disease-Specific Health Status With Long-Term Survival in Peripheral Artery Disease.J. Am. Heart Assoc.2022114e02223210.1161/JAHA.121.02223235132874
     [Google Scholar]
  34. MurphyT.P. ReynoldsM.R. CohenD.J. RegensteinerJ.G. MassaroJ.M. CutlipD.E. MohlerE.R. CerezoJ. OldenburgN.C. ThumC.C. GoldbergS. HirschA.T. Correlation of patient-reported symptom outcomes and treadmill test outcomes after treatment for aortoiliac claudication.J. Vasc. Interv. Radiol.201324101427143510.1016/j.jvir.2013.05.05723906799
     [Google Scholar]
  35. FowkesF.G. MurrayG.D. ButcherI. HealdC.L. LeeR.J. ChamblessL.E. FolsomA.R. HirschA.T. DramaixM. deBackerG. WautrechtJ.C. KornitzerM. NewmanA.B. CushmanM. Sutton-TyrrellK. FowkesF.G. LeeA.J. PriceJ.F. d’AgostinoR.B. MurabitoJ.M. NormanP.E. JamrozikK. CurbJ.D. MasakiK.H. RodríguezB.L. DekkerJ.M. BouterL.M. HeineR.J. NijpelsG. StehouwerC.D. FerrucciL. McDermottM.M. StoffersH.E. HooiJ.D. KnottnerusJ.A. OgrenM. HedbladB. WittemanJ.C. BretelerM.M. HuninkM.G. HofmanA. CriquiM.H. LangerR.D. FronekA. HiattW.R. HammanR. ResnickH.E. GuralnikJ. McDermottM.M. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis.JAMA2008300219720810.1001/jama.300.2.19718612117
     [Google Scholar]
  36. HoeksS.E. SmolderenK.G. Scholte op ReimerW.J.M. VerhagenH.J.M. SpertusJ.A. PoldermansD. Clinical validity of a disease-specific health status questionnaire: The Peripheral Artery Questionnaire.J. Vasc. Surg.200949237137710.1016/j.jvs.2008.08.08919028064
     [Google Scholar]
  37. HammadT.A. SmolderenK.G. SpertusJ.A. JonesP.G. ShishehborM.H. Associations of exercise ankle–brachial index, pain-free walking distance and maximum walking distance with the Peripheral Artery Questionnaire: Finding from the PORTRAIT PAD Registry.Vasc. Med.2019241324010.1177/1358863X1878502629992849
     [Google Scholar]
  38. MalikA.O. Poghni Peri-Okonny GoschK. ThomasM.B. Mena-HurtadoC. HiattW. AronowH.D. JonesP.G. ProvanceJ. LabroscianoC. JelaniQ. SpertusJ.A. SmolderenK.G. Association of perceived stress with health status outcomes in patients with peripheral artery disease.J. Psychosom. Res.202114011031310.1016/j.jpsychores.2020.11031333279876
     [Google Scholar]
  39. KimB.H. ChoK.I. SpertusJ. ParkY.H. JeH.G. ShinM.S. LeeJ.H. JangJ.S. Peripheral artery questionnaire improves ankle brachial index screening in symptomatic patients with peripheral artery disease.Int. J. Clin. Pract.201468121488149510.1111/ijcp.1249425358955
     [Google Scholar]
  40. JohnstonA.L. VemulapalliS. GoschK.L. AronowH.D. AbbottJ.D. PatelM.R. SmolderenK.G. ShisheborM. SpertusJ.A. JonesW.S. Ankle-brachial index in patients with intermittent claudication is a poor indicator of patient-centered and clinician-based evaluations of functional status.J. Vasc. Surg.201969390691210.1016/j.jvs.2018.07.03930626552
     [Google Scholar]
  41. VogelT.R. BraetD.J. KruseR.L. BathJ. WangJ. GoschK. SmolderenK.G. Level of disease and association with health status in patients presenting with claudication from the PORTRAIT registry.J. Vasc. Surg.20207262017202610.1016/j.jvs.2020.03.04232325227
     [Google Scholar]
  42. JeH. KimB. ChoK. JangJ. ParkY. SpertusJ. Correlation between patient-reported symptoms and ankle-brachial index after revascularization for peripheral arterial disease.Int. J. Mol. Sci.2015165113551136810.3390/ijms16051135525993299
     [Google Scholar]
  43. SukulD. GreyS.F. HenkeP.K. GurmH.S. GrossmanP.M. Heterogeneity of ankle-brachial indices in patients undergoing revascularization for critical limb ischemia.JACC Cardiovasc. Interv.201710222307231610.1016/j.jcin.2017.08.02629169498
     [Google Scholar]
  44. BeckmanJ.A. SchneiderP.A. ConteM.S. Advances in revascularization for peripheral artery disease: Revascularization in PAD.Circ. Res.2021128121885191210.1161/CIRCRESAHA.121.31826134110904
     [Google Scholar]
  45. StegP.G. BhattD.L. WilsonP.W.F. D’AgostinoR.Sr OhmanE.M. RötherJ. LiauC.S. HirschA.T. MasJ.L. IkedaY. PencinaM.J. GotoS. One-year cardiovascular event rates in outpatients with atherothrombosis.JAMA2007297111197120610.1001/jama.297.11.119717374814
     [Google Scholar]
  46. ShinoharaY. NishimaruK. SawadaT. TerashiA. HandaS. HiraiS. HayashiK. TohgiH. FukuuchiY. UchiyamaS. YamaguchiT. KobayashiS. KondoK. OtomoE. GotohF. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS).Stroke20083961827183310.1161/STROKEAHA.107.50513118388340
     [Google Scholar]
  47. ShinoharaY. NishimaruK. Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: Differential efficacy in diabetes? Subgroup analysis from S-ACCESS.Stroke20094082862286510.1161/STROKEAHA.109.55424619520981
     [Google Scholar]
  48. ParkS.Y. RheeS.Y. OhS. KwonH.S. ChaB.Y. LeeH.J. LeeH.C. KimY.S. Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes.Endocr. J.201259870971610.1507/endocrj.EJ12‑004722673600
     [Google Scholar]
  49. NagayamaD. OhiraM. SaikiA. ShiraiK. TatsunoI. Sarpogrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients.Int. Heart J.201455433734110.1536/ihj.13‑37724898600
     [Google Scholar]
  50. GoyalR.K. ElimbanV. XuY.J. KumamotoH. TakedaN. DhallaN.S. Mechanism of sarpogrelate action in improving cardiac function in diabetes.J. Cardiovasc. Pharmacol. Ther.2011163-438038710.1177/107424841038470821183729
     [Google Scholar]
  51. LuY. LiJ. XieJ. YuQ. LiaoL. Effects of sarpogrelate hydrochloride on peripheral arterial disease.Medicine (Baltimore)20199846e1726610.1097/MD.000000000001726631725602
     [Google Scholar]
  52. RiederM. GauchelN. BodeC. DuerschmiedD. Serotonin: a platelet hormone modulating cardiovascular disease.J. Thromb. Thrombolysis2021521424710.1007/s11239‑020‑02331‑033155668
     [Google Scholar]
  53. MarcinkowskaM. KubackaM. ZagorskaA. JarominA. Fajkis-ZajaczkowskaN. KolaczkowskiM. Exploring the antiplatelet activity of serotonin 5-HT2A receptor antagonists bearing 6-fluorobenzo[d]isoxazol-3-yl)propyl) motif– as potential therapeutic agents in the prevention of cardiovascular diseases.Biomed. Pharmacother.202214511242410.1016/j.biopha.2021.11242434785417
     [Google Scholar]
  54. WeberR. DienerH.C. Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.J. Cell. Mol. Med.201014102371238010.1111/j.1582‑4934.2010.01162.x20738445
     [Google Scholar]
  55. MalloyR.J. KanaanA.O. SilvaM.A. DonovanJ.L. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.Clin. Ther.2013351014901500.e710.1016/j.clinthera.2013.09.00424139421
     [Google Scholar]
  56. NohY. LeeJ. ShinS. LimH.S. BaeS.K. OhE. KimG.J. KimJ.H. LeeS. Antiplatelet therapy of cilostazol or sarpogrelate with aspirin and clopidogrel after percutaneous coronary intervention: A retrospective cohort study using the Korean national health insurance claim database.PLoS One2016113e015047510.1371/journal.pone.015047526939062
     [Google Scholar]
  57. ShimizuY. MinatoguchiS. HashimotoK. UnoY. AraiM. WangN. ChenX. LuC. TakemuraG. ShimomuraM. FujiwaraT. FujiwaraH. The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts.J. Am. Coll. Cardiol.20024071347135510.1016/S0735‑1097(02)02158‑712383585
     [Google Scholar]
  58. ParkK.Y. OhE. KwakM.K. JunH.S. HeoT.H. Pravastatin and sarpogrelate synergistically ameliorate atherosclerosis in LDLr-knockout mice.PLoS One2016113e015079110.1371/journal.pone.015079126950217
     [Google Scholar]
  59. FujitaM. MizunoK. HoM. TsukaharaR. MiyamotoA. MikiO. IshiiK. MiwaK. Sarpogrelate treatment reduces restenosis after coronary stenting.Am. Heart J.20031453E1610.1067/mhj.2003.17612660685
     [Google Scholar]
  60. UchiyamaS. OzakiY. SatohK. KondoK. NishimaruK. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.Cerebrovasc. Dis.2007242-326427010.1159/00010513517622759
     [Google Scholar]
  61. ShimizuK. SunagawaY. FunamotoM. HondaH. KatanasakaY. MuraiN. KawaseY. HirakoY. KatagiriT. YabeH. ShimizuS. SariN. WadaH. HasegawaK. MorimotoT. The selective serotonin 2A receptor antagonist sarpogrelate prevents cardiac hypertrophy and systolic dysfunction via inhibition of the ERK1/2–GATA4 signaling pathway.Pharmaceuticals (Basel)20211412126810.3390/ph1412126834959669
     [Google Scholar]
  62. KimD. ChoiB. KuS.K. ParkJ. OhE. KwakM.K. Beneficial effects of sarpogrelate and rosuvastatin in high fat diet/streptozotocin-induced nephropathy in mice.PLoS One2016114e015396510.1371/journal.pone.015396527097221
     [Google Scholar]
  63. KuC.A. RyalsR.C. JiangD. CoynerA.S. WellerK.K. SinhaW. RobbB.M. YangP. PennesiM.E. The role of ERK1/2 activation in sarpogrelate-mediated neuroprotection.Invest. Ophthalmol. Vis. Sci.201859146247110.1167/iovs.17‑2315929368005
     [Google Scholar]
  64. SuY. MaoN. LiM. DongX. LinF.Z. XuY. LiY.B. Sarpogrelate inhibits the expression of ICAM-1 and monocyte–endothelial adhesion induced by high glucose in human endothelial cells.Mol. Cell. Biochem.20133731-219519910.1007/s11010‑012‑1490‑923111892
     [Google Scholar]
  65. SunY.M. SuY. JinH.B. LiJ. BiS. Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress.Int. J. Cardiol.2011147338338710.1016/j.ijcard.2009.09.53919883950
     [Google Scholar]
  66. XuY.J. ZhangM. JiL. ElimbanV. ChenL. DhallaN.S. Suppression of high lipid diet induced by atherosclerosis sarpogrelate.J. Cell. Mol. Med.201216102394240010.1111/j.1582‑4934.2012.01554.x22348587
     [Google Scholar]
  67. ShikataC. NemotoM. EbisawaT. NishiyamaA. TakedaN. Effect of sarpogrelate on cardiovascular disorders.Exp. Clin. Cardiol.2011163757622065937
     [Google Scholar]
  68. HidakaS. KobayashiS. IwagamiM. IsshikiR. TsutsumiD. MochidaY. IshiokaK. OkaM. MaesatoK. MoriyaH. OhtakeT. Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease.Ren. Fail.2013351434810.3109/0886022X.2012.73475823110683
     [Google Scholar]
  69. NorgrenL. JawienA. MátyásL. RiegerH. AritaK. Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European study.Vasc. Med.2006112758310.1191/1358863x06vm657oa16886837
     [Google Scholar]
  70. LeeJ.Y. LeeS.W. LeeW.S. HanS. ParkY.K. KwonC.H. JangJ.Y. ChoY.R. ParkG.M. AhnJ.M. KimW.J. ParkD.W. KangS.J. KimY.H. LeeC.W. ParkS.W. ParkS.J. Prevalence and clinical implications of newly revealed, asymptomatic abnormal ankle-brachial index in patients with significant coronary artery disease.JACC Cardiovasc. Interv.20136121303131310.1016/j.jcin.2013.08.00824355120
     [Google Scholar]
  71. MaB. FanX. LiuP. Therapeutic effects of medication use on intermittent claudication: A network meta-analysis.J. Cardiovasc. Pharmacol.202177225326210.1097/FJC.000000000000095633235027
     [Google Scholar]
  72. SogaY. ShintaniY. HamasakiT. TomoiY. TakaokaJ. SuematsuN. YokoiH. AndoK. Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study.Cardiovasc. Interv. Ther.201732432533210.1007/s12928‑016‑0414‑027456034
     [Google Scholar]
  73. AhnS. LeeJ. MinS.K. HaJ. MinS. KimS.Y. ChoM.J. ChoS. SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.Trials201718143910.1186/s13063‑017‑2155‑528938905
     [Google Scholar]
  74. JungS.J. ShimS.R. KimB.J. JungJ.M. Antiplatelet regimens for Asian patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis.Ann. Transl. Med.20219975310.21037/atm‑20‑795134268366
     [Google Scholar]
/content/journals/cvp/10.2174/0115701611285172241015074050
Loading
Efficacy and Safety of Sarpogrelate on Symptom Improvement in Patients with Peripheral Arterial Disease (PAD) and/or Being at Risk of PAD: A Single Arm, Multi-Centered, Open-Label Trial
Curr. Vasc. Pharmacol. 23, 45 (2025); https://doi.org/10.2174/0115701611285172241015074050
/content/journals/cvp/10.2174/0115701611285172241015074050
/content/journals/cvp/10.2174/0115701611285172241015074050
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): 5-HT2A receptor; ankle-brachial Index; efficacy evaluation analysis group; peripheral arterial disease; peripheral artery questionnaire; Sarpogrelate

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test